Developer docs
API playgroundTry for free, no card

Search company profiles

TME Pharma

Full company profile

uuid0002hzu

Namestring
TME Pharma
Legal namestring
TME Pharma N.V.
Websiteurl
tmepharma.com
Company typeenum
Public
Founded yearint
1997
Descriptiontext

TME Pharma N.V. (formerly NOXXON Pharma N.V.) is a clinical-stage biotechnology company headquartered in Berlin, Germany, founded in 1997 and publicly listed on Euronext Growth Paris under the ticker ALTME. The company develops biostable aptamers using its proprietary Spiegelmer platform technology — L-stereoisomer RNA/DNA oligonucleotides (mirror-image nucleic acids) that directly bind and neutralize chemokine targets in the extracellular space. The pipeline centers on two clinical-stage candidates: NOX-A12 (olaptesed pegol), a CXCL12 inhibitor in mid-stage development for glioblastoma and pancreatic cancer, and NOX-E36 (emapticap pegol), a CCL2 inhibitor being evaluated for ophthalmology indications through a partnership with the Singapore Eye Research Institute. The company's lead asset, NOX-A12, has demonstrated clinically meaningful activity in the GLORIA Phase 1/2 trial, where combination therapy with radiotherapy and bevacizumab produced median overall survival of 19.9 months versus 9.5 months for standard of care (p=0.003) in newly-diagnosed MGMT-unmethylated glioblastoma — data published in Nature Communications in 2026. NOX-A12 has received FDA Fast Track Designation, FDA Orphan Drug Designation, and EMA Orphan Drug Designation for glioblastoma.

TME Pharma's commercial strategy is partnership-driven rather than independent commercialization. The company is actively pursuing outlicensing of NOX-A12 and NOX-E36, with prior or current collaborations with Merck/MSD (OPTIMUS Phase 2 in pancreatic cancer), the U.S. National Cancer Institute (preclinical brain tumor research), University Hospital Bonn, NCT Heidelberg, and the Singapore Eye Research Institute. Revenue is not generated from product sales; the company's primary funding sources are dilutive equity raises, convertible debt (notably from Atlas Special Opportunities and Kreos Capital/BlackRock), and non-dilutive grants (including a €2.4M German Federal grant for the NOX-A12 Phase 2 trial).

The company employs between 51 and 100 people, has 94,188,981 shares outstanding (June 2025), and reports a cash runway extending to Q2 2027. The most significant recent operational shifts include a CEO transition in June 2025 (Aram Mangasarian from CEO to CSO; Diede van den Ouden as new CEO) and a November 2025 non-binding LOI with a German resource development company to explore diversification into sustainable tailings reprocessing and environmental rehabilitation as a cash-flow-generating side initiative.

Short descriptiontext

TME Pharma N.V. is a clinical-stage German biotechnology company developing proprietary L-RNA aptamer (Spiegelmer) therapeutics that neutralize chemokines in the tumor microenvironment, with lead candidate NOX-A12 in glioblastoma and pancreatic cancer and NOX-E36 in ophthalmology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBerlin, Germany
HQ citystring
Berlin
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage oncology therapeutics, RNA aptamer drug development, tumor microenvironment targeting, chemokine inhibitor therapeutics, Spiegelmer biopharmaceuticals
Industry2 codes
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-stage Oncology Biopharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Outlicensing/partnership deals
TypeLicensing Royalties
Description

TME Pharma is seeking to outlicense its lead compounds NOX-A12 and NOX-E36 to pharmaceutical partners. The company is in active partnership discussions for NOX-A12 licensing with financial runway extending to Q2 2027.

tmepharma.com
2Strategic transactions
TypeLicensing Royalties
Description

The company is pursuing alternative funding sources including spin-out or strategic transactions for both compounds to achieve positive operational cash flow.

tmepharma.com
3Government/academic grants
TypeLicensing Royalties
Description

TME Pharma received a €2.4 million German Federal grant to support NOX-A12 Phase 2 trial in brain cancer (October 2024).

tmepharma.com
4Investment income
TypeLicensing Royalties
Description

The company signed a non-binding LOI with a German resource development company to explore collaboration in sustainable tailings reprocessing and environmental rehabilitation projects as part of its strategy to diversify into cash-flow-generating asset investments.

tmepharma.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Spiegelmer
Description

Proprietary L-RNA aptamer technology platform developed by TME Pharma for generating therapeutic compounds.

tmepharma.com
+2 more records
Core offering1 text field

TME Pharma is a clinical-stage biotechnology company developing Spiegelmer-based L-RNA aptamer drug candidates that target chemokines in the tumor microenvironment. Its lead candidate NOX-A12 (olaptesed pegol) neutralizes CXCL12 and is in Phase 1/2 development for glioblastoma and Phase 2 for pancreatic cancer, while NOX-E36 (emapticap pegol) neutralizes CCL2 and is being evaluated for ophthalmic anti-fibrotic applications. The company intends to outlicense its candidates to pharmaceutical partners rather than commercialize them directly.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Median overall survival doubled to 19.9 months vs 9.5 months standard of care in glioblastoma patients receiving NOX-A12 + radiotherapy + anti-VEGF
+5 more records
Product overview1 text field

TME Pharma is a clinical-stage biotechnology company developing novel therapies for the most aggressive cancers, specializing in approaches targeting the tumor microenvironment (TME). The company's portfolio centers on two Spiegelmer-based drug candidates: NOX-A12 (olaptesed pegol), a CXCL12 inhibitor in mid-stage clinical development for glioblastoma and pancreatic cancer, and NOX-E36 (emapticap pegol), a CCL2 inhibitor being evaluated for ophthalmic diseases. Both candidates work by modulating the tumor microenvironment to break tumor protection barriers against the immune system and block tumor repair. The proprietary Spiegelmer platform technology enables the development of L-RNA aptamers that bind and neutralize chemokine targets in the extracellular space.

Product and service2 records
1NOX-A12 (olaptesed pegol)
CategoryClinical-stage oncology drug candidate (CXCL12 inhibitor)
Description

NOX-A12 is an intravenously administered, PEGylated L-stereoisomer RNA aptamer (Spiegelmer) that directly binds and neutralizes CXCL12 (C-X-C Chemokine Ligand 12). It is TME Pharma's lead clinical candidate in mid-stage development for glioblastoma (Phase 1/2 GLORIA trial) and pancreatic cancer (Phase 2 OPTIMUS trial with Merck/MSD's Keytruda), working by neutralizing chemokines in the tumor microenvironment to break tumor protection and block tumor repair when combined with radiotherapy and other treatments.

2NOX-E36 (emapticap pegol)
CategoryClinical-stage ophthalmology/oncology drug candidate (CCL2 inhibitor)
Description

NOX-E36 is an injectable PEGylated L-stereoisomer RNA aptamer (Spiegelmer) that directly binds and neutralizes the chemokine CCL2 (MCP-1) and three related chemokines. It has completed Phase 1 and Phase 2 clinical studies and is being evaluated for ophthalmic diseases with high need for anti-fibrotic therapies, particularly in collaboration with the Singapore Eye Research Institute for glaucoma filtration surgery applications.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1German Resource Development Company (GRDC)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-05
Description

TME Pharma signed a non-binding Letter of Intent with a German resource development company to explore potential collaboration and investment in sustainable tailings reprocessing and environmental rehabilitation projects. The deal is part of TME Pharma's strategy to diversify into cash-flow-generating asset investments.

globenewswire.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-06-18
Description

TME Pharma signed an option framework agreement with Singapore Eye Research Institute for the ophthalmology development of NOX-E36. The collaboration follows preclinical data published by SERI researchers showing NOX-E36's anti-fibrotic mode of action in an animal model relevant to glaucoma filtration surgery.

3U.S. National Cancer Institute (NCI)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-13
Description

TME Pharma collaborates with the U.S. National Cancer Institute, part of the National Institutes of Health, to explore the effects of NOX-A12 (CXCL12 inhibitor) and NOX-E36 (CCL2 inhibitor) individually and combined on brain tumors. The research program is led by Dr. Mark R. Gilbert, Chief of the Neuro-Oncology Branch at NCI's Center for Cancer Research. NCI conducts preclinical testing in different combinations with immunomodulatory treatments including immune checkpoint inhibitors in three murine brain cancer models.

tmepharma.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-21
Description

TME Pharma and Merck & Co./MSD announced their second clinical collaboration for a Phase 2 trial evaluating NOX-A12 in combination with MSD's anti-PD-1, Keytruda (pembrolizumab), and two different chemotherapy regimens as second-line therapy in patients with microsatellite stable pancreatic cancer. Previously collaborated on OPERA Phase 1/2 trial with Keytruda in metastatic pancreatic and colorectal cancer.

5National Center for Tumor Diseases (NCT) Heidelberg
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2017-05-16
Description

TME Pharma collaborated with Prof. Dr. Dirk Jäger and Dr. Niels Halama at the National Center for Tumor Diseases in Heidelberg, one of Europe's leading centers for cancer research and treatment, to conduct the completed clinical trial in metastatic colorectal and pancreatic cancer.

tmepharma.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

TME Pharma collaborates with Prof. Dr. Michael Hölzel, Director at the Institute for Experimental Oncology at University Hospital Bonn, on the ongoing GLORIA study. His research focuses on the complexity and dynamics of cellular and non-cellular interactions within the tumor microenvironment with particular focus on neural crest derived tumors. Prof. Hölzel leads research to characterize NOX-A12-mediated modulation of tumor microenvironment in glioblastoma patients by multiparameter immunofluorescence microscopy.

7Prof. Dr. Frank A. Giordano
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Prof. Dr. Frank A. Giordano, Professor and Chair of the Department of Radiation Oncology at the University Medical Center Mannheim, is the lead investigator of the GLORIA trial. He is an expert in precision radiation therapy and intraoperative irradiation of malignant tumors and has received international recognition for his brain tumor research, including an award from ASTRO and honorary membership of SEOR.

globenewswire.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Aprea Therapeutics is a US-based clinical-stage oncology company developing small-molecule reactivators of mutant p53. It is a comparable small-cap clinical-stage oncology company with multiple programs, similar partnership-driven strategy, and similar capital-markets dependency.

TypeEmerging player
Description

Cantargia is a Sweden-based clinical-stage biotech developing antibodies targeting IL1RAP, with oncology programs in pancreatic cancer and other solid tumors. It is a small European clinical-stage oncology company with a similar out-licensing/partnership strategy and tumor-microenvironment-related biology.

TypeDirect peer
Description

Chimerix is a US clinical-stage oncology company that acquired Oncoceutics (founded by TME Pharma board member Dr. Lee Schalop) for $78M plus milestones in 2021, validating the brain-cancer asset-acquisition model. Chimerix's small-molecule oncology pipeline and focus on CNS tumors make it a relevant strategic comparator.

TypeDirect peer
Description

X4 Pharmaceuticals is a commercial-stage biotech developing oral CXCR4 antagonists (mavorixafor, approved for WHIM syndrome; in trials for chronic neutropenia and other indications). It targets the same chemokine receptor pathway as TME Pharma's NOX-A12 (CXCL12/CXCR4 axis), making it the most directly comparable peer in mechanism and therapeutic hypothesis.

TypeEmerging player
Description

Isofol Medical is a Sweden-based clinical-stage oncology company developing arfolitixorin for colorectal cancer. Its former CEO (Dr. Jungnelius) is now TME Pharma's CMO, and both companies share the Nordic/European clinical-stage oncology profile and partnered development model.

TypeDirect peer
Description

Oncopeptides is a clinical-stage/specialty oncology company developing peptide-based therapies for hematological cancers (melflufen/Pepaxto). It is a similarly-sized European clinical-stage oncology company with a novel mechanism of action, comparable in scale, geography, and pipeline-stage dynamics to TME Pharma.

TypeDirect peer
Description

BioLineRx developed motixafortide (Aphexda), a CXCR4 antagonist approved in 2023 for stem-cell mobilization in multiple myeloma and explored in pancreatic cancer and other solid tumors. It is the closest late-stage/approved competitor on the CXCR4 mechanism that TME Pharma's NOX-A12 is also pursuing.

TypeDirect peer
Description

Ryvu Therapeutics is a Poland-based clinical-stage oncology company developing small-molecule kinase inhibitors and immunometabolic therapies. A senior board member of TME Pharma (Dr. Jungnelius) also serves on Ryvu's board, and both companies share the European clinical-stage oncology profile and similar scale.

TypeOthers
Description

NeoVentures Biotechnology is a Canada-based aptamer technology company developing DNA/RNA aptamers for research, diagnostic, and select therapeutic applications. It is a relevant technology-platform peer to TME Pharma's Spiegelmer platform, though much smaller and with a research-tools focus.

TypeEmerging player
Description

SomaLogic, now part of Standard BioTools, is the leading aptamer-based proteomics company (SOMAmer reagents), directly comparable to TME Pharma's Spiegelmer platform in core technology (modified/aptamer-based molecular recognition), though SomaLogic's commercial focus is diagnostics rather than therapeutics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds17 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TME Pharma

Clinical-stage Oncology Biopharmaceuticalstmepharma.com

TME Pharma N.V. is a clinical-stage German biotechnology company developing proprietary L-RNA aptamer (Spiegelmer) therapeutics that neutralize chemokines in the tumor microenvironment, with lead candidate NOX-A12 in glioblastoma and pancreatic cancer and NOX-E36 in ophthalmology.

What TME Pharma does

TME Pharma N.V. (formerly NOXXON Pharma N.V.) is a clinical-stage biotechnology company headquartered in Berlin, Germany, founded in 1997 and publicly listed on Euronext Growth Paris under the ticker ALTME. The company develops biostable aptamers using its proprietary Spiegelmer platform technology — L-stereoisomer RNA/DNA oligonucleotides (mirror-image nucleic acids) that directly bind and neutralize chemokine targets in the extracellular space. The pipeline centers on two clinical-stage candidates: NOX-A12 (olaptesed pegol), a CXCL12 inhibitor in mid-stage development for glioblastoma and pancreatic cancer, and NOX-E36 (emapticap pegol), a CCL2 inhibitor being evaluated for ophthalmology indications through a partnership with the Singapore Eye Research Institute. The company's lead asset, NOX-A12, has demonstrated clinically meaningful activity in the GLORIA Phase 1/2 trial, where combination therapy with radiotherapy and bevacizumab produced median overall survival of 19.9 months versus 9.5 months for standard of care (p=0.003) in newly-diagnosed MGMT-unmethylated glioblastoma — data published in Nature Communications in 2026. NOX-A12 has received FDA Fast Track Designation, FDA Orphan Drug Designation, and EMA Orphan Drug Designation for glioblastoma.

TME Pharma's commercial strategy is partnership-driven rather than independent commercialization. The company is actively pursuing outlicensing of NOX-A12 and NOX-E36, with prior or current collaborations with Merck/MSD (OPTIMUS Phase 2 in pancreatic cancer), the U.S. National Cancer Institute (preclinical brain tumor research), University Hospital Bonn, NCT Heidelberg, and the Singapore Eye Research Institute. Revenue is not generated from product sales; the company's primary funding sources are dilutive equity raises, convertible debt (notably from Atlas Special Opportunities and Kreos Capital/BlackRock), and non-dilutive grants (including a €2.4M German Federal grant for the NOX-A12 Phase 2 trial).

The company employs between 51 and 100 people, has 94,188,981 shares outstanding (June 2025), and reports a cash runway extending to Q2 2027. The most significant recent operational shifts include a CEO transition in June 2025 (Aram Mangasarian from CEO to CSO; Diede van den Ouden as new CEO) and a November 2025 non-binding LOI with a German resource development company to explore diversification into sustainable tailings reprocessing and environmental rehabilitation as a cash-flow-generating side initiative.

TME Pharma firmographics

Firmographics
Name
TME Pharma
Legal name
TME Pharma N.V.
Website
https://tmepharma.com
Company type
Public
Founded year
1997
Operating status
Operating
Headcount range
11–50 employees
Short description
TME Pharma N.V. is a clinical-stage German biotechnology company developing proprietary L-RNA aptamer (Spiegelmer) therapeutics that neutralize chemokines in the tumor microenvironment, with lead candidate NOX-A12 in glioblastoma and pancreatic cancer and NOX-E36 in ophthalmology.
Ownership category
akta.pro rank

TME Pharma industry classification

Industry
Product category
Clinical-stage Oncology Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Clinical-stage oncology therapeutics
  • RNA aptamer drug development
  • Tumor microenvironment targeting
  • Chemokine inhibitor therapeutics
  • Spiegelmer biopharmaceuticals

Where TME Pharma is headquartered

Location

Headquarters

HQ city
Berlin
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

TME Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Outlicensing/partnership deals: TME Pharma is seeking to outlicense its lead compounds NOX-A12 and NOX-E36 to pharmaceutical partners. The company is in active partnership discussions for NOX-A12 licensing with financial runway extending to Q2 2027.
  2. Strategic transactions: The company is pursuing alternative funding sources including spin-out or strategic transactions for both compounds to achieve positive operational cash flow.
  3. Government/academic grants: TME Pharma received a €2.4 million German Federal grant to support NOX-A12 Phase 2 trial in brain cancer (October 2024).
  4. Investment income: The company signed a non-binding LOI with a German resource development company to explore collaboration in sustainable tailings reprocessing and environmental rehabilitation projects as part of its strategy to diversify into cash-flow-generating asset investments.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

TME Pharma product offering

Product offering

Core offering

TME Pharma is a clinical-stage biotechnology company developing Spiegelmer-based L-RNA aptamer drug candidates that target chemokines in the tumor microenvironment. Its lead candidate NOX-A12 (olaptesed pegol) neutralizes CXCL12 and is in Phase 1/2 development for glioblastoma and Phase 2 for pancreatic cancer, while NOX-E36 (emapticap pegol) neutralizes CCL2 and is being evaluated for ophthalmic anti-fibrotic applications. The company intends to outlicense its candidates to pharmaceutical partners rather than commercialize them directly.

Product overview

TME Pharma is a clinical-stage biotechnology company developing novel therapies for the most aggressive cancers, specializing in approaches targeting the tumor microenvironment (TME). The company's portfolio centers on two Spiegelmer-based drug candidates: NOX-A12 (olaptesed pegol), a CXCL12 inhibitor in mid-stage clinical development for glioblastoma and pancreatic cancer, and NOX-E36 (emapticap pegol), a CCL2 inhibitor being evaluated for ophthalmic diseases. Both candidates work by modulating the tumor microenvironment to break tumor protection barriers against the immune system and block tumor repair. The proprietary Spiegelmer platform technology enables the development of L-RNA aptamers that bind and neutralize chemokine targets in the extracellular space.

Differentiator

Problem solved

Functional benefit

Brands

  • Spiegelmer: Proprietary L-RNA aptamer technology platform developed by TME Pharma for generating therapeutic compounds.
  • NOX-A12 (olaptesed pegol)
  • NOX-E36 (emapticap pegol)

Products and services

  • NOX-A12 (olaptesed pegol) NOX-A12 is an intravenously administered, PEGylated L-stereoisomer RNA aptamer (Spiegelmer) that directly binds and neutralizes CXCL12 (C-X-C Chemokine Ligand 12). It is TME Pharma's lead clinical candidate in mid-stage development for glioblastoma (Phase 1/2 GLORIA trial) and pancreatic cancer (Phase 2 OPTIMUS trial with Merck/MSD's Keytruda), working by neutralizing chemokines in the tumor microenvironment to break tumor protection and block tumor repair when combined with radiotherapy and other treatments.
  • NOX-E36 (emapticap pegol) NOX-E36 is an injectable PEGylated L-stereoisomer RNA aptamer (Spiegelmer) that directly binds and neutralizes the chemokine CCL2 (MCP-1) and three related chemokines. It has completed Phase 1 and Phase 2 clinical studies and is being evaluated for ophthalmic diseases with high need for anti-fibrotic therapies, particularly in collaboration with the Singapore Eye Research Institute for glaucoma filtration surgery applications.

Quantifiable outcome

  • Median overall survival doubled to 19.9 months vs 9.5 months standard of care in glioblastoma patients receiving NOX-A12 + radiotherapy + anti-VEGF
  • +5 more outcomes

Companies that use TME Pharma

Customer profile

Segments3 records

Ideal customer profiles3 records

TME Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

TME Pharma partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered minor, major and core.

  • German Resource Development Company (GRDC)minorStrategic or Co-development Partner · 5 November 2025TME Pharma signed a non-binding Letter of Intent with a German resource development company to explore potential collaboration and investment in sustainable tailings reprocessing and environmental rehabilitation projects. The deal is part of TME Pharma's strategy to diversify into cash-flow-generating asset investments.
  • Singapore Eye Research Institute (SERI)majorStrategic or Co-development Partner · 18 June 2025TME Pharma signed an option framework agreement with Singapore Eye Research Institute for the ophthalmology development of NOX-E36. The collaboration follows preclinical data published by SERI researchers showing NOX-E36's anti-fibrotic mode of action in an animal model relevant to glaucoma filtration surgery.
  • U.S. National Cancer Institute (NCI)coreStrategic or Co-development Partner · 13 June 2022TME Pharma collaborates with the U.S. National Cancer Institute, part of the National Institutes of Health, to explore the effects of NOX-A12 (CXCL12 inhibitor) and NOX-E36 (CCL2 inhibitor) individually and combined on brain tumors. The research program is led by Dr. Mark R. Gilbert, Chief of the Neuro-Oncology Branch at NCI's Center for Cancer Research. NCI conducts preclinical testing in different combinations with immunomodulatory treatments including immune checkpoint inhibitors in three murine brain cancer models.
  • Merck & Co. / MSDcoreStrategic or Co-development Partner · 21 July 2021TME Pharma and Merck & Co./MSD announced their second clinical collaboration for a Phase 2 trial evaluating NOX-A12 in combination with MSD's anti-PD-1, Keytruda (pembrolizumab), and two different chemotherapy regimens as second-line therapy in patients with microsatellite stable pancreatic cancer. Previously collaborated on OPERA Phase 1/2 trial with Keytruda in metastatic pancreatic and colorectal cancer.
  • National Center for Tumor Diseases (NCT) HeidelbergmajorStrategic or Co-development Partner · 16 May 2017TME Pharma collaborated with Prof. Dr. Dirk Jäger and Dr. Niels Halama at the National Center for Tumor Diseases in Heidelberg, one of Europe's leading centers for cancer research and treatment, to conduct the completed clinical trial in metastatic colorectal and pancreatic cancer.
  • University Hospital Bonn (Prof. Dr. Michael Hölzel)coreStrategic or Co-development PartnerTME Pharma collaborates with Prof. Dr. Michael Hölzel, Director at the Institute for Experimental Oncology at University Hospital Bonn, on the ongoing GLORIA study. His research focuses on the complexity and dynamics of cellular and non-cellular interactions within the tumor microenvironment with particular focus on neural crest derived tumors. Prof. Hölzel leads research to characterize NOX-A12-mediated modulation of tumor microenvironment in glioblastoma patients by multiparameter immunofluorescence microscopy.
  • Prof. Dr. Frank A. GiordanocoreStrategic or Co-development PartnerProf. Dr. Frank A. Giordano, Professor and Chair of the Department of Radiation Oncology at the University Medical Center Mannheim, is the lead investigator of the GLORIA trial. He is an expert in precision radiation therapy and intraoperative irradiation of malignant tumors and has received international recognition for his brain tumor research, including an award from ASTRO and honorary membership of SEOR.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

TME Pharma competitors and assessment

Company assessment

Emerging players

  • Aprea Therapeutics: Aprea Therapeutics is a US-based clinical-stage oncology company developing small-molecule reactivators of mutant p53. It is a comparable small-cap clinical-stage oncology company with multiple programs, similar partnership-driven strategy, and similar capital-markets dependency.
  • Cantargia: Cantargia is a Sweden-based clinical-stage biotech developing antibodies targeting IL1RAP, with oncology programs in pancreatic cancer and other solid tumors. It is a small European clinical-stage oncology company with a similar out-licensing/partnership strategy and tumor-microenvironment-related biology.
  • Isofol Medical: Isofol Medical is a Sweden-based clinical-stage oncology company developing arfolitixorin for colorectal cancer. Its former CEO (Dr. Jungnelius) is now TME Pharma's CMO, and both companies share the Nordic/European clinical-stage oncology profile and partnered development model.
  • SomaLogic (Standard BioTools): SomaLogic, now part of Standard BioTools, is the leading aptamer-based proteomics company (SOMAmer reagents), directly comparable to TME Pharma's Spiegelmer platform in core technology (modified/aptamer-based molecular recognition), though SomaLogic's commercial focus is diagnostics rather than therapeutics.

Direct peers

  • Chimerix: Chimerix is a US clinical-stage oncology company that acquired Oncoceutics (founded by TME Pharma board member Dr. Lee Schalop) for $78M plus milestones in 2021, validating the brain-cancer asset-acquisition model. Chimerix's small-molecule oncology pipeline and focus on CNS tumors make it a relevant strategic comparator.
  • X4 Pharmaceuticals: X4 Pharmaceuticals is a commercial-stage biotech developing oral CXCR4 antagonists (mavorixafor, approved for WHIM syndrome; in trials for chronic neutropenia and other indications). It targets the same chemokine receptor pathway as TME Pharma's NOX-A12 (CXCL12/CXCR4 axis), making it the most directly comparable peer in mechanism and therapeutic hypothesis.
  • Oncopeptides: Oncopeptides is a clinical-stage/specialty oncology company developing peptide-based therapies for hematological cancers (melflufen/Pepaxto). It is a similarly-sized European clinical-stage oncology company with a novel mechanism of action, comparable in scale, geography, and pipeline-stage dynamics to TME Pharma.
  • BioLineRx: BioLineRx developed motixafortide (Aphexda), a CXCR4 antagonist approved in 2023 for stem-cell mobilization in multiple myeloma and explored in pancreatic cancer and other solid tumors. It is the closest late-stage/approved competitor on the CXCR4 mechanism that TME Pharma's NOX-A12 is also pursuing.
  • Ryvu Therapeutics: Ryvu Therapeutics is a Poland-based clinical-stage oncology company developing small-molecule kinase inhibitors and immunometabolic therapies. A senior board member of TME Pharma (Dr. Jungnelius) also serves on Ryvu's board, and both companies share the European clinical-stage oncology profile and similar scale.

Others

  • NeoVentures Biotechnology: NeoVentures Biotechnology is a Canada-based aptamer technology company developing DNA/RNA aptamers for research, diagnostic, and select therapeutic applications. It is a relevant technology-platform peer to TME Pharma's Spiegelmer platform, though much smaller and with a research-tools focus.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

TME Pharma social profiles

Digital presence

TME Pharma compliance and trust

Trust signal

Compliance2 records

TME Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TME Pharma leadership team

Management profile

Number of profiles

Profiles6 records

TME Pharma funding detail

Funding detail

Funding overview

Funding rounds17 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TME Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TME Pharma

What does TME Pharma do?

TME Pharma is a clinical-stage biotechnology company developing Spiegelmer-based L-RNA aptamer drug candidates that target chemokines in the tumor microenvironment. Its lead candidate NOX-A12 (olaptesed pegol) neutralizes CXCL12 and is in Phase 1/2 development for glioblastoma and Phase 2 for pancreatic cancer, while NOX-E36 (emapticap pegol) neutralizes CCL2 and is being evaluated for ophthalmic anti-fibrotic applications. The company intends to outlicense its candidates to pharmaceutical partners rather than commercialize them directly.

Is TME Pharma a public or private company?

TME Pharma is a public company. It is classified as public and is currently operating.

When was TME Pharma founded?

TME Pharma was founded in 1997. It employs 11 to 50 people.

Where is TME Pharma based?

TME Pharma is headquartered in Berlin, Germany, in the Europe region.

How does TME Pharma make money?

Four revenue lines are on record. Outlicensing/partnership deals are the primary driver. The others are strategic transactions, government/academic grants and investment income.

Who are TME Pharma's main competitors?

Emerging players on record are Aprea Therapeutics, Cantargia, Isofol Medical and SomaLogic (Standard BioTools). Direct peers are Chimerix, X4 Pharmaceuticals, Oncopeptides, BioLineRx and Ryvu Therapeutics. NeoVentures Biotechnology is listed as an others.

Does TME Pharma have an API?

No public API is recorded for TME Pharma.

What industry is TME Pharma in?

TME Pharma's product category is Clinical-stage Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireTME Pharma signe un accord de négociation exclusif et contraignant avec la société japonaise TMS Co., Ltd.TME Pharma signed an exclusive negotiation agreement with Japanese biotech TMS Co., Ltd. for its NOX-A12 glioblastoma drug, paying €150,000 for six months of exclusivity. The deal includes €10 million in short-term payments and over €100 million in regulatory and commercial milestones, with royalties of 8-10% on sales peaking at $1 billion.GlobeNewswireTME Pharma Signs Binding Exclusive Negotiation Agreement with Japanese TMS Co., Ltd.TME Pharma signed a binding exclusive negotiation agreement with Japanese TMS Co., Ltd. for worldwide rights to NOX-A12, paying €150,000 for six months of exclusivity. The deal includes near-term payments of about €10M, over €100M in milestones, and 8-10% royalties on sales projected to peak at $1 billion. The partnership aims to restart the Phase 2 GLORIA study.FierceBiotechTME holds onto $1B dream for brain cancer drug as search for partners nears conclusionBerlin-based TME Pharma said on Aug. 24 it has narrowed its search for a partner for NOX-A12, a CCL2 inhibitor for brain cancer, to two suitors in the final evaluation phase of advanced discussions. The company, which entered the year with €2 million in cash, aims to license the drug for phase 2 development, citing potential peak sales of $1 billion.FinanzNachrichten.dePress Release: TME Pharma provides update on its activitiesTME Pharma has entered the final evaluation phase of discussions with two potential partners to license its flagship drug NOX-A12 for glioblastoma treatment. The company also announced it discontinued a collaboration with GRDC and reported that CEO Diede van den Ouden sold shares pursuant to a pre-set instruction.BioSpaceMinutes of the TME Pharma Annual General MeetingTME Pharma's annual general meeting on June 15, 2026, unanimously adopted all resolutions. The company highlighted its lead compounds NOX-A12 and NOX-E36, with NOX-A12 in glioblastoma trials and NOX-E36 for eye diseases. It is seeking funds to unlock their value.GlobeNewswireCompte-rendu de l’assemblée générale de TME PharmaTME Pharma N.V. held its annual shareholder meeting on June 15, 2026, in Berlin, Germany, where all resolutions presented by the board were unanimously adopted. Four shareholders were present, representing 6.87% of total shares and voting rights. The company, led by CEO Diede van den Ouden who joined in June 2025, is undergoing strategic restructuring to advance its clinical-stage oncology candidates NOX-A12 and NOX-E36.GlobeNewswireMinutes of the TME Pharma Annual General MeetingTME Pharma N.V. held its Annual General Meeting on June 15, 2026, in Berlin, Germany, chaired by Mr. Diede van den Ouden, where all resolutions submitted by the Board of Directors were unanimously adopted by shareholders representing 6.87% of shares and voting rights. The clinical-stage biotechnology company, which specializes in developing novel therapies for brain cancer and eye diseases, is actively seeking to outlicense its lead compounds NOX-A12 and NOX-E36 while pursuing alternative funding sources to achieve positive operational cash flow.GlobeNewswireMinutes of the TME Pharma Annual General MeetingTME Pharma's annual general meeting on June 15, 2026, unanimously adopted all resolutions. Shareholders representing 6.87% of voting rights voted, with results posted on the company website. The company seeks funding to outlicense its NOX-A12 and NOX-E36 assets.BioSpaceTME Pharma publishes its annual financial results and annual reportTME Pharma published its FY2025 results, reporting a net loss of €3.3M and negative equity of €1.6M. The company has no revenue and extended loan maturities to Q2 2027. It is seeking licensing or partnerships for its lead assets NOX-A12 and NOX-E36.GlobeNewswireTME Pharma publishes its annual financial results and annual reportTME Pharma published its FY2025 results, reporting a net loss of €3.3M and negative equity of €1.6M. The company has no revenues and extended loan maturities to Q2 2027. It is seeking licensing or partnerships for its lead assets NOX-A12 and NOX-E36.